Dr Reddys Laboratories Ltd (NYSE: RDY)

Dr. Reddy's Laboratories Limited is an integrated global pharmaceutical company committed to accelerating access to affordable and innovative medicines. The company operates across the pharmaceutical value chain developing manufacturing and marketing products that treat conditions ranging from common ailments to complex diseases. With operations spanning North America Europe India and emerging markets Dr. Reddy's delivers therapeutic solutions through its diversified business model focused on accessibility and patient outcomes.

Dr. Reddy's Laboratories Limited generates revenue primarily through the sale of pharmaceutical products across its three core business segments. The Global Generics segment contributes the majority of income from finished dosage forms including prescription medications and over-the-counter products. The Pharmaceutical Services and Active Ingredients segment earns revenue from active pharmaceutical ingredient sales and contract manufacturing services provided to third parties. The Others segment derives income from biotechnology research milestones and proprietary product commercialization. In the fiscal year ended March 31 2025 the company reported total revenue of Rs 325,535 million demonstrating the scale of its diversified operations.

The company operates through the following segments: Global Generics; Pharmaceutical Services and Active Ingredients ("PSAI"); and Others.

• Global Generics: This segment encompasses the manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for patient consumption. It includes both branded formulations sold under specific names and generic equivalents that match reference drugs in safety efficacy and quality. The segment additionally incorporates the company's biologics business developing biosimilar alternatives to reference biological products and the Nicotine Replacement Therapy business acquired from Haleon which offers products for smoking cessation.

• Pharmaceutical Services and Active Ingredients (PSAI): This segment focuses on the production of active pharmaceutical intermediates and active pharmaceutical ingredients essential for drug formulation. It provides these core chemicals to both internal manufacturing operations and external clients including generic drug manufacturers. The segment further offers contract research development and manufacturing services supporting innovator companies through the drug development process from early discovery to commercial scale production with capabilities spanning small molecules and complex biologics.

• Others: This segment consists of Aurigene Oncology Limited a biotechnology subsidiary engaged in discovering and developing novel therapeutic candidates particularly in oncology and inflammation through advanced research platforms. It also includes the Proprietary Products business which concentrates on creating differentiated formulations through research partnerships and commercializes these innovations via milestone based payments and royalty arrangements when products reach market.

Dr. Reddy's Laboratories Limited maintains a strong competitive position as one of the world's leading generic pharmaceutical companies with significant scale in multiple therapeutic areas. The company holds a top ten ranking in the Indian pharmaceutical market with a 3.1% share according to IQVIA data and is recognized as a major player in emerging markets including Russia where it ranks seventeenth with 1.7% market share. Dr. Reddy's competes with established firms such as Cipla Limited Sun Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited and Lupin Limited while differentiating itself through its vertically integrated operations that control quality from raw materials to finished products and its strategic focus on developing complex generics and biosimilars for regulated markets.

Dr. Reddy's Laboratories Limited serves patients healthcare providers and institutional customers through a global distribution network. The company supplies its products to approximately 5,900 wholesalers who distribute to retail pharmacies and maintains relationships with hospital systems for direct supply of critical care medications. Its customer base includes individual consumers purchasing over-the-counter remedies patients receiving prescription treatments through healthcare providers and government health programs purchasing vaccines and essential medicines. The company reaches these diverse customers across its key geographic markets including the United States India Russia European nations and various regions in Africa Asia and Latin America where it addresses local health needs through tailored product offerings.